Disclosure
DAI summary · Not investment advice
Dongkoo Bio & Pharma will terminate its KRW 3.0 billion treasury share trust early on Oct 28, 2026, after acquiring 822,134 shares.
Commentary
AI commentary · Not investment advice
What happened
Dongkoo Bio & Pharma will terminate early, on October 28, 2026, its KRW 3.0 billion treasury share trust agreement with NH Investment & Securities Co., Ltd. The reason given is that the treasury share acquisition has been completed. The agreement was originally set to run from July 22, 2026 to January 21, 2027, and the board resolution date is also October 28, 2026.
In the company's terms
Relative to the company, the completed acquisition covers 822,134 common shares. The filing gives a ratio of 3.3% against market capitalization. The trust is being ended before its original term expires because the purchases are done.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist